The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials
Abstract
Background: Several randomized clinical trials in chronic myeloid leukemia (CML) have reported better patient survival with interferon alfa (IFN α) than with standard chemotherapeutic agents, such as busulfan or hydroxyurea. However, the size and persistence of this survival benefit is uncertain. Our aim was to assess these reliably, both overall and in particular patient subgroups. Methods: We collaborated in a worldwide overview of all clinical trials in which patients with CML were randomly assigned to receive either IFN α as the main drug or standard chemotherapy. Trials were identified by electronic and hand searching of the medical literature and databases and by personal contact. Individual patient data were available for each of 1554 patients who had been randomly assigned to treatment in seven trials (German, Italian, British, French, Japanese, and “Benelux”). Intentionto- treat stratified logrank survival analyses were performed, reporting two-sided P values. Results: Almost all of the patients in these trials had disease with the Philadelphia chromosome abnormality. Among those who did, the regimens that involved IFN α produced a statistically significantly better survival than those involving either hydroxyurea ( P = .001) or busulfan ( P = .00007) alone. The 5-year survival rates were 57% with IFN α and 42% with chemotherapy, with an absolute difference of 15% (standard deviation = 3%; P <.00001). There were no trials or subgroups of patients in which the treatment difference was statistically significantly different from the average. Conclusion: For patients with Philadelphia chromosome-positive chronic myeloid leukemia, the inclusion of IFN α in the therapeutic regimen produced substantially better 5-year survival than standard chemotherapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G., Robertson, J., Tso, C., Braun, T., Clarkson, B., & Cervantes, F. (1984) · Blood · doi:10.1182/blood.v63.4.789.789 · Cited by 1,214
Secondary prevention of vascular disease by prolonged antiplatelet treatment
Antiplatelet Trialists' Collaboration (1988) · BMJ · doi:10.1136/bmj.296.6618.320 · Cited by 1,047
(1994) · New England Journal of Medicine · doi:10.1056/nejm199403243301204 · Cited by 577
Practical methodology of meta‐analyses (overviews) using updated individual patient data
Stewart, L. A., & Cochrane Working Group On Meta‐Analysis Using Individual Patient Data (1995) · Statistics in Medicine · doi:10.1002/sim.4780141902 · Cited by 492
Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H., Pralle, H., Hossfeld, D., Queisser, W., Loffler, H., Hochhaus, A., & Heinze, B. (1994) · Blood · doi:10.1182/blood.v84.12.4064.bloodjournal84124064 · Cited by 448
Allan, N. C., Shepherd, P. C. A., & Richards, S. M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92596-1 · Cited by 388
Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H., Pralle, H., Hossfeld, D., Queisser, W., Loffler, H., Heinze, B., & Georgii, A. (1993) · Blood · doi:10.1182/blood.v82.2.398.398 · Cited by 223
Ohnishi, K., Ohno, R., Tomonaga, M., Kamada, N., Onozawa, K., Kuramoto, A., Dohy, H., Mizoguchi, H., MIYAWAKI, S., & Tsubaki, K. (1995) · Blood · doi:10.1182/blood.v86.3.906.906 · Cited by 190
British Journal of Haematology
British Society for Haematology, & European Hematology Association (2010) · British Journal of Haematology · doi:10.1111/(issn)1365-2141 · Cited by 73
Cited by
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Metadata
- Authors
- Chronic Myeloid Leukemia Trialists' Collaborative Group
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-11-05
- Volume
- 89
- Issue
- 21
- Pages
- 1616-1620
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2508058084
- Cited by
- 283
- References
- 12
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials. https://app.cochat.ai/papers/10.1093/jnci/89.21.1616
- The paper
- Chronic Myeloid Leukemia Trialists' Collaborative Group. (1997). Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/89.21.1616
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.